الفهرس 
LIVER FIBROSISOnly 14 pages are availabe for public view
 |  | from | 200 |  |  |
| | | from | 200 | | |
Abstract
ABSTRACT
Background: Platelet Derived Growth Factor Receptor beta (PDGFRβ) has been associated to hepatic stellate cell activation and has been the target of multiple therapeutic studies. However, little is known concerning its use as a diagnostic agent.
Objective: To evaluate the value of sPDGFRβ based-score in predicting liver fibrosis stage in Egyptian patients with NAFLD and viral liver disease in correlation with NAFLD fibrosis score and Fibro-Scan.
Methods: Circulating PDGFRβ levels were analysed in a case control study of patients with liver fibrosis/cirrhosis due to viral hepatitis, and non-alcoholic fatty liver disease (NAFLD), who were classified regarding fibrosis by fibroscan. The diagnostic performance of PDGFRβ as individual blood parameter, and in combination with other metabolic factors was evaluated and compared to previously validated clinical fibrosis scores Fib-4, APRI, and AST/ALT ratio in both groups of patients, and to NAFLD fibrosis score in patients with NAFLD.
Findings: sPDGFRβ levels are progressively increased with increasing fibrosis stage and the largest difference was observed in patients with significant fibrosis, compared to no or mild fibrosis. The accuracy of sPDGFRβ-levels predicting fibrosis could be increased by combining it with albumin levels and platelet counts into a novel diagnostic algorithm, the PRTA-score, generating a predictive value superior to Fib-4, APRI, and AST/ALT in both NAFLD and viral liver disease, and superior to NAFLD fibrosis score in group of NAFLD. Finally, we confirmed the diagnostic value of sPDGFRβ levels and the PRTA-score in a case control study in detecting significant liver fibrosis in NAFLD and viral liver disease.
Interpretation: The PRTA-score is an accurate tool for detecting significant liver fibrosis in patients with viral liver disease and non-alcoholic fatty liver disease (NAFLD).